ImmuneRegen BioSciences, a development-stage biotechnology company and a wholly owned subsidiary of IR BioSciences Holdings, Inc. (IRBS.OB), announced the company’s submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to begin human clinical testing of Homspera® for the treatment of Idiopathic Pulmonary Fibrosis.

Currently afflicting 5 million people worldwide and killing 40,000 people annually, Idiopathic Pulmonary Fibrosis is a progressive interstitial lung disease characterized by scarring of lung tissue and over time prevents the lung from effectively transferring oxygen into the bloodstream. Homspera® is an adult stem cell active compound that has shown the ability to regenerate and strengthen the immune system as well as enhance wound healing. Homspera® has also been shown to affect a number of immunological and non-immunological cell types via its receptor-binding activity at the neurokinin-1 receptor (NK-1R).

ImmuneRegen BioSciences CEO, Michael K. Wilhelm, commented, “This marks a major milestone in our efforts to explore the molecular mechanisms and capabilities of Homspera and its potential to treat a range of complications arising from damage to the immune system.” He added, “We are encouraged by the results of pre-clinical studies of Homspera and look forward to taking our research to this next important level.”